JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

Lyell Immunopharma Inc

Chiusa

19.54 -4.68

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

19.27

Massimo

20.64

Metriche Chiave

By Trading Economics

Entrata

-102M

-141M

Vendite

-9K

6K

EPS

-7.68

Margine di Profitto

-2,345,383.333

Dipendenti

300

EBITDA

-23M

-59M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+90.79% upside

Dividendi

By Dow Jones

Utili prossimi

11 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-14M

528M

Apertura precedente

24.22

Chiusura precedente

19.54

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Lyell Immunopharma Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

30 apr 2026, 23:08 UTC

Utili

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr 2026, 23:07 UTC

Utili

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr 2026, 22:20 UTC

Utili

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 apr 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 apr 2026, 23:47 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

30 apr 2026, 23:47 UTC

Discorsi di Mercato

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 apr 2026, 23:27 UTC

Discorsi di Mercato

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 apr 2026, 23:22 UTC

Utili

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 apr 2026, 23:20 UTC

Discorsi di Mercato

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 apr 2026, 22:52 UTC

Utili

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr 2026, 22:33 UTC

Utili

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 apr 2026, 22:32 UTC

Utili

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 apr 2026, 22:32 UTC

Utili

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 apr 2026, 22:24 UTC

Acquisizioni, Fusioni, Takeovers

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 apr 2026, 22:23 UTC

Acquisizioni, Fusioni, Takeovers

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 apr 2026, 22:23 UTC

Acquisizioni, Fusioni, Takeovers

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 apr 2026, 22:23 UTC

Acquisizioni, Fusioni, Takeovers

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 apr 2026, 22:11 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

30 apr 2026, 22:11 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

30 apr 2026, 22:11 UTC

Discorsi di Mercato

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 apr 2026, 22:05 UTC

Utili

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 apr 2026, 21:57 UTC

Utili

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 apr 2026, 21:56 UTC

Utili

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 apr 2026, 21:56 UTC

Utili

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 apr 2026, 21:55 UTC

Utili

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 apr 2026, 21:54 UTC

Utili

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 apr 2026, 21:54 UTC

Utili

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 apr 2026, 21:53 UTC

Utili

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 apr 2026, 21:49 UTC

Utili

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 apr 2026, 21:49 UTC

Utili

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Confronto tra pari

Modifica del prezzo

Lyell Immunopharma Inc Previsione

Obiettivo di Prezzo

By TipRanks

90.79% in crescita

Previsioni per 12 mesi

Media 41 USD  90.79%

Alto 45 USD

Basso 34 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Lyell Immunopharma Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.4217 / 0.4691Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

No Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

help-icon Live chat